<DOC>
	<DOCNO>NCT00909480</DOCNO>
	<brief_summary>This trial conduct Asia , South America United States America ( USA ) . The aim clinical trial determine whether two insulin treatment give daily equally effective respect blood glucose lower effect subject type 2 diabetes inadequately control metformin treatment without additional anti-diabetic drug ( OAD ) .</brief_summary>
	<brief_title>Effect Insulin Detemir Insulin Glargine Blood Glucose Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosed type 2 diabetes least 6 month Stable treatment total daily dose least 1500 mg metformin maximum tolerate dose ( minimum 1000 mg ) without one OAD ( sulphonylureas , meglitinides , thiazolidinediones dipeptidyl peptidase4 ( DPP4 ) inhibitor ) least 3 month Subject insulinnaive ( shortterm insulin treatment 14 day allow ) HbA1c ( glycosylated haemoglobin ) 7.09.0 % ( inclusive ) central laboratory analysis ( one retest within one week allow ) Body Mass Index ( BMI ) less equal 35.0 kg/m^2 Any contraindication insulin detemir insulin glargine accord local labelling Receipt investigational product within 4 week Anticipated change dose systemic treatment product , Investigator 's opinion could interfere glucose metabolism ( e.g . systemic corticosteroid ) Clinically significant disease , Investigator 's opinion may confound result trial pose additional risk administer trial product Any condition Investigator feel would interfere trial participation evaluation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>